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ABSTRACT
Background: Docosahexaenoic acid (DHA) kinetics appear to
change with intake, which is an effect that we studied in an older
population by using uniformly carbon-13–labeled DHA (13C-DHA).
Objective:We evaluated the influence of a fish-oil supplement over
5 mo on the kinetics of 13C-DHA in older persons.
Design: Thirty-four healthy, cognitively normal participants (12
men, 22 women) aged between 52 and 90 y were recruited. Two
identical kinetic studies were performed, each with the use of a single
oral dose of 40 mg 13C-DHA. The first kinetic study was performed
before participants started taking a 5-mo supplementation that provided
1.4 g DHA/d plus 1.8 g eicosapentaenoic acid (EPA)/d (baseline); the
second study was performed during the final month of supplementation
(supplement). In both kinetic studies, blood and breath samples were
collected #8 h and weekly over 4 wk to analyze 13C enrichment.
Results: The time 3 supplement interaction for 13C-DHA in the
plasma was not significant, but there were separate time and sup-
plement effects (P , 0.0001). The area under the curve for plasma
13C-DHA was 60% lower while subjects were taking the supple-
ment than at baseline (P , 0.0001). The uniformly carbon-13–
labeled EPA concentration was 2.6 times higher 1 d posttracer while
patients were taking the supplement than at baseline. The mean
(6SEM) plasma½AQ1 13C-DHA half-life was 4.5 6 0.4 d at baseline
compared with 3.0 6 0.2 d with the supplement (P , 0.0001).
Compared with at baseline, the mean whole-body half-life was
61% lower while subjects were taking the supplement. The loss
of 13C-DHA through b oxidation to carbon dioxide labeled with
carbon-13 increased from 0.085% of dose/h at baseline to 0.208%
of dose/h while subjects were taking the supplement.
Conclusions: In older persons, a supplement of 3.2 g EPA + DHA/d
increased b oxidation of 13C-DHA and shortened the plasma 13C-DHA
half-life. Therefore, when circulating concentrations½AQ2 of EPA and DHA
are increased, more DHA is available for b oxidation. This trial was
registered at clinicaltrials.gov as NCT01577004. Am J Clin Nutr
2014;100:1–8.
INTRODUCTION
From currently available dose-response studies, it has been
generally accepted that the amount of DHA in plasma total lipids
and/or½AQ3 phospholipids tends to level off when the intake of DHA
and EPA is .1000 mg/d (1), whereas at ,1000 mg/d, the DHA
plasma dose-response relation is generally linear (2, 3). One expla-
nation for the plateau effect of DHA and EPA doses .1000 mg/d is
that DHA is potentially more b oxidized, but to our knowledge, this
possibility has not previously been shown experimentally. Indeed,
regardless of the dietary intake of DHA and EPA, the kinetics of
DHA in humans are still poorly understood.
In humans, the kinetics of DHA in plasma and its b oxidation
can be evaluated by using an oral dose of uniformly carbon-13–
labeled DHA (13C-DHA)4. Plasma 13C-DHA kinetics in humans
were first reported more than a decade ago (4–6). In one study,
a single oral dose of 250–280 mg 13C–fatty acid mixture in
which 13C-DHA represented 44% of the total labeled fatty acids
was given in the form of triglyceride (5). Two hours postdose,
13C-DHA reached a maximum in plasma triglycerides in 3
healthy men (5). The apparent retroconversion of 13C-DHA to
uniformly carbon-13–labeled EPA (13C-EPA) was estimated to
be equivalent to 1.4% of the plasma concentration of 13C-DHA
(5). Neither b oxidation nor the 13C-DHA half-life were re-
ported in the studies (4–6). We recently reported the metabolism
of a single 50-mg dose of 99% pure 13C-DHA methyl ester
given to 6 young and 6 older humans (7). We showed that 4 h
after 13C-DHA intake, older participants had a 4-fold higher
13C-DHA concentration in plasma total lipids compared with
that of the young participants (7). In older persons supplemented
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with 323 mg EPA + 680 mg DHA for 3 wk, the unlabeled DHA
in plasma total lipids reached a plateau 7 d earlier than in young
adults (8). Therefore, the DHA homeostasis seems to be disturbed
in older persons, which is a situation that could both influence risk
of cognitive decline (9, 10) and, in turn, be influenced by a pre-
existing cognitive decline. The objective of the current study was
to evaluate the influence of fish-oil supplementation on 13C-DHA
kinetics in healthy, cognitively normal older persons.
SUBJECTS AND METHODS
Participants were .50 y old, which was an age chosen to
represent the population that could potentially benefit from
DHA intake in preventing cognitive decline and cardiovascular
diseases (11, 12). All participants completed the Mini-Mental
State Examination before and 4 mo after starting the supplement
and were cognitively normal for their age (13). Exclusion cri-
teria were diabetes, a cancer diagnosis in the past 6 mo, low
serum albumin, liver or renal disease, uncontrolled hyperthy-
roidism or hypothyroidism, an autoimmune disorder, or C-reactive
protein concentration .10 mg/L. Women had to be post-
menopausal to be enrolled in this study. Because we previously
showed that 13C-DHA kinetics are not the same in APOE3 and
APOE4 carriers (14), we excluded APOE4 carriers from the
current study. Other exclusion criteria included smoking, the use
of n23 PUFA supplements, overt heart disease or a cardiac
event 6 mo before the study, and use of long-action benzodi-
azepines, warfarin, Coumadin, or a fibrate. At baseline, all
participants reported having consumed#2 portions fatty fish/wk
(eg, of salmon, herring, or sardines). At baseline, the mean
percentage of DHA in plasma total lipids was 1.6 6 0.5%,
which indicated that DHA intake was #150 mg/d (15, 16).
During the study, participants recorded fatty fish consumption in
a logbook.
All participants gave informed written consent before starting
the study. The study was approved by the Human Ethics Research
Committee of the Health and Social Sciences Center–Sherbrooke
University Geriatrics Institute.
Experimental design
The 13C-DHA tracer used in this study was uniformly 13C
labeled (.98%) and of high chemical purity (99%). The 13C-
DHA was synthesized by using microalgae grown in the pres-
ence of 13C-glucose according to the method of Le et al (17).
Each dose comprised 40 mg 13C-DHA methyl ester that, before
use, was stored in an individual glass ampoule sealed under
argon.
The design of the overall study and the 2 embedded kinetic
studies is presented in Figure 1. There were 2 matching 28-d
kinetic studies that used 13C-DHA as follows: one study took
place before subjects started taking the supplement (ie, base-
line), and one study took place during the last month of sup-
plementation with EPA and DHA (ie, supplement). The
supplement consisted of 4 3 1.3-g capsules of fish oil that
provided 1.8 g EPA/d plus 1.4 g DHA ethyl ester/d ½AQ4(Ocean
Nutrition Canada). We have shown that at least a 28-d follow-up
is needed for the plasma 13C-DHA concentration to return to
near baseline after 13C-DHA has been consumed orally (7, 14).
The 28-d kinetic study started by the collection of fasting blood
FIGURE 1. Overall study design (top) and design of the embedded kinetic studies (bottom). The kinetic studies were performed before (baseline) and in the
past month of an n23 fatty acid supplementation (supplement) providing 1.8 g/d EPA + 1.4 g/d DHA for 5 mo. In kinetic studies, a single oral dose of 40 mg
13C-DHAwas given to participants after collection of a fasted blood sample (time 0 h of day 0, represented by the upward-facing open arrow). The collection
of blood and breath samples after 13C-DHA intake was done at 1, 2, 4, 6, and 8 h of day 0, and a fasted blood and breath sample was collected at days 1, 7, 14,
21, and 28. 13C-DHA, uniformly carbon-13–labeled DHA.
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and breath samples (0 h), after which each participant received
a single oral dose of 40 mg 13C-DHA deposited on a piece of
toast consumed at breakfast. Breakfast comprised 2 pieces of
whole-wheat toast with peanut butter, one scrambled egg, one
apple, 35 g mozzarella cheese, and 250 mL orange juice. The
macronutrient composition of this 670-kcal breakfast was 25.5 g
fat, 78 g carbohydrate, and 29 g protein. The breakfast including
the tracer was consumed by all participants within 15 min. Four
hours after breakfast, participants were given a lunch consisting
of store-bought lasagna with 200 mL vegetable juice and a ce-
real bar. The macronutrient composition of this 500-kcal lunch
was 15 g fat, 88 g carbohydrate, and 23 g protein.
Blood and breath samples were collected at 0, 1, 2, 4, 6, and 8 h
on day 0 and days 1, 7, 14, 21, and 28 postdose (Figure 1). A
catheter was installed in each participant’s forearm to collect the
first 6 samples during day 0. Blood samples were collected by
using a 5-mL syringe (Becton Dickinson) and transferred into 4
mL EDTA-coated tubes (Becton Dickinson). The tubes were
centrifuged at 2300 3 g for 15 min at 48C, and plasma was
stored in 3 0.5 mL Eppendorf tubes at 2808C until additional
analysis. Alveolar breath samples at rest were collected by
having subjects breath into a device that consisted of a perfo-
rated plastic bag attached to a mouthpiece (Easysampler;
Quintron Instrument Co) to which an evacuated tube could be
inserted to collect a sample of the exhaled breath (7, 14). These
breath samples were used to follow the appearance of carbon




Concentrations of 13C-DHA and 13C-EPA were measured in
plasma total lipids. Plasma total lipids were analyzed instead of
separating by lipid classes (phospholipids, triglycerides, cho-
lesteryl esters, and free fatty acids) because of the absence of
a significant modification in concentrations of triglycerides, total
cholesterol, HDL cholesterol ,and LDL cholesterol while sub-
jects were taking the supplement than at baseline (Table 1).
Total lipids were extracted from 0.25 mL plasma by using
Folch’s method (18). Heptadecanoate was added as an internal
standard to quantify fatty acids. The plasma total lipid extract
was saponified by using 1 mol KOH in methanol/L½AQ5 and heated at
908C for 1 h, which released fatty acids from cholesteryl esters
and glycerolipids. After cooling to room temperature, hexane
and saline were added. The hexane phase that contained cho-
lesterol was discarded and the remaining saline plus fatty acid
salt mixture was acidified with hydrogen chloride to obtain free
fatty acids; the latter were extracted with hexane. Fatty acid
methyl esters were generated by adding boron trifluoride/
methanol (14%; Sigma-Aldrich) to the free fatty acids and
heated at 908C for 30 min. Fatty acid methyl esters were ana-
lyzed by using a gas chromatograph (model 6890; Agilent)
equipped with a 50-m BPX-70 fused capillary column (SGE).
The injection and flame-ionization detection were performed at
2508C, and the oven-temperature program was 508C for 2 min,
increased to 1708C at 208C/min, held there for 15 min, finally
increased to 2108C at 58C/min, and held there for 7 min. Helium
was the carrier gas, and the inlet pressure was 233 kPa at 508C.
Standard mixtures of fatty acids were used to identify individual
fatty acids [NuChek 68A, NuChek 411, and NuChek 455 (Nu-
Chek Prep Inc) plus a custom mixture of SFAs]. The 13C-DHA
enrichment in plasma total lipids was performed by using gas
chromatography–combustion isotope ratio mass spectrometry as
previously described (19). 13C/12C values ½AQ6at each time were
compared with 13C/12C at baseline (t = 0 of day 0) to calculate
the d per mil values, which were designated thereafter as the
atom percent excess. The Actual 13C enrichment in plasma DHA
and EPA was calculated from atom percent excess values ac-
cording to Brossard et al (5).
The enrichment of 13C in expired-breath CO2 was analyzed by
using isotope ratio mass spectrometry (Europa 20–20; Sercon
Ltd) as previously described (20). Helium (Praxair) was the
carrier gas, and 5% CO2/N2 was used as the reference gas. The
ratio of 13C:12C-CO2 was used to calculate the b oxidation of
13C-DHA recovered in the breath in the form of 13C-CO2. The
percentage of dose of 13C-DHA recovered in the breath as 13C-
CO2 was calculated as previously described (21) except that
basal metabolism was evaluated by using indirect calorimetry
(CCM/D; Medgraphics Corp) to measure the volume of carbon
dioxideCO2 and O2 exhaled by participants over 30 min as
previously described (22). The cumulative 13C-DHA b oxidation
was calculated as the AUC of the percentage of dose recovered
(PDR) at each time point (GraphPad Prism 5 software; Graph-
Pad). Specific activities of plasma DHAwere calculated by using
the ratio of 13C-DHA (nmol/mL plasma) to uniformly carbon-12–
labeled DHA (12C-DHA; nmol/mL plasma) times 100.
The 13C-DHA half-life in plasma was calculated as pre-
viously described (14). The whole-body 13C-DHA half-life was
estimated by using cumulative b-oxidation curves from days 1–
28 postdose (14). For some participants, a cumulative b oxidation
of 50% was not reached within 28 d, and thus in those cases, it
was assumed that cumulative 13C-CO2 data .28 d would be
linear (see Figure 4). With the use of cumulative 13C-CO2 data at
time points 1, 7, 14, 21, and 28 d postdose, a linear equation was
calculated for each participant to estimate the whole-body half-
life defined as the time needed to reach a 50% cumulative b
oxidation of the 13C-DHA dose recovered as 13C-CO2. Correla-
tions between plasma 13C-DHA and the percentage of dose of
13C-DHA recovered as breath 13C-CO2 were performed for each
TABLE 1
Anthropometric characteristics and blood biochemistry of healthy older




(n = 34) t test
Age (y) 72.4 6 8.92 — —
Sex (M/F) (n) 12/22
MMSE (/30)3 28.7 6 1.3 28.8 6 1.3 0.635
Blood biochemistry n = 34 n = 22
Glucose (mmol/L) 4.7 6 0.6 4.7 6 0.7 0.553
Triglycerides (mmol/L) 1.4 6 0.8 1.3 6 0.5 0.200
Total cholesterol (mmol/L) 4.9 6 0.8 4.8 6 0.9 0.268
HDL cholesterol (mmol/L) 1.5 6 0.4 1.5 6 0.4 0.251
LDL cholesterol (mmol/L) 2.8 6 0.7 2.8 6 0.8 0.393
TC:HDL cholesterol 3.5 6 0.9 3.5 6 1.0 0.064
1 Statistics was performed by using a paired t test. There was no sig-
nificant difference (P , 0.05) while subjects were taking the supplement
than at baseline for any of the blood biochemistry markers.
2Mean 6 SD (all such values).
3MMSE: Mini-Mental State Examination.
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participant by using hierarchical linear models (measured within
persons). The slope of the correlation between plasma 13C-DHA
and the percentage of dose of 13C-DHA recovered as breath 13C-
CO2 were calculated and compared between baseline and while
subjects were taking the supplement.
Statistics
To calculate the sample size, we used the AUC of plasma 13C-
DHA as the primary endpoint. From a previous published article
that used 13C-DHA in older person, the mean AUC was 230 6
63 nmol $ L21 $ h21½AQ7 (7). We did not have data to estimate the
AUC while subjects were taking the supplement, and thus, we
set the effect size at 0.5, and the d SD was set at 63 nmol $ L21 $
h21 with the assumption that the correlation (r) of the AUC at
baseline compared with when subject were taking the supple-
ment was equal to 0.5, which was conservative. We also set the
power at 80% by using a paired t test with a 0.05 two-sided
significance. With the use of these data, the number of partici-
pants was n = 28, but we anticipated a dropout of 20%, and thus,
the number of participants recruited was n = 34. During the
study, there were no dropouts. See supplemental Figure 1 under
“Supplemental data” in the online issue for a presentation of
a Consolidated Standards of Reporting Trials–like flowchart that
shows the flow of data through the kinetic studies.
All data from plasma and breath are presented as means 6
SEMs. Data from blood and breath samples collected during
kinetic studies were analyzed by using the PROC MIXED
procedure implemented in SAS 9.2 software (SAS) (14). Instead
of a classical 2-factor ANOVA, the PROC MIXED procedure
was used to optimize the use of all data over time and maintain
statistical power. This procedure allowed for the testing of the
effect of time as a repeated measure, supplementation as a fixed
factor (baseline compared with supplement), and the interaction
time 3 supplement. Student paired t tests were performed for
plasma and whole-body half-lives and to detect significant dif-
ferences in anthropometric characteristics and the blood bio-
chemistry of participants while they were taking the supplement
than at baseline (SPSS 17.0; SPSS Inc). AUCs were calculated
with GraphPad Prism 5 for Windows software (version 5.03;
GraphPad½AQ8 ). Hierarchical linear models (measured within per-
sons) were performed with HLM for Windows v 7.0. This
multilevel model addresses within-subject and between subject
variability simultaneously from a pair of submodels (23). The
dependent variable was the percentage of dose of 13C-DHA
recovered as 13C-CO2 in the breath per hour. Independent var-
iables were 13C-DHA in plasma and the supplement. See sup-
plemental Text under “Supplemental data” in the online issue for
a presentation of the mathematical modeling. Statistical signif-
icance was set at P # 0.05.
RESULTS
Participants
Therewere 12men and 22womenwith an age range of 52–90 y in
the study (Table 1). Their mean (6SEM) score on the Mini-Mental
State Examination was 29 6 1 both at baseline and while subjects
were taking the supplement, which confirming that subjects were
cognitively normal throughout the study. Blood biochemistry was
performed on 34 subjects at baseline and 22 subjects while they were
taking the supplement. Initially, it was intended that blood bio-
chemistry be performed to evaluate the eligibility of participants only
at baseline. Thereafter, the protocol was amended to include a sec-
ond evaluation of blood biochemistry while participants were taking
the supplement, but the first 12 participants had already completed
the study. Blood glucose, triglycerides, total cholesterol, HDL cho-
lesterol, LDL cholesterol, and total cholesterol/HDL cholesterol did
not significantly change while subjects were taking the supplement
than at baseline (Table 1). During the 5 mo that subject were taking
the supplement, all participants reported the consumption of ,2
portions fatty fish/wk. At baseline, means of plasma EPA and DHA
were 117 6 52 and 183 6 70 nmol/mL, respectively, which rep-
resented 0.95 6 0.38% and 1.60 6 0.53% of total fatty acids, re-
spectively (see supplemental Table 1 under “Supplemental data” in
the online issue). One month after subject started supplementation,
EPA and DHA plateaued in total lipids of plasma at concentrations
between 383 and 589 nmol/mL for EPA and between 290 and 376
nmol/mL for DHA (Figure 2).
13C-DHA kinetics
At baseline, plasma 13C-DHA peaked 6 h postdose at 2.0 6
0.2 nmol/mL, whereas it peaked 4 h postdose at 1.66 0.1 nmol/mL
when subjects were taking the supplement (Figure 3A). The time3
supplement interaction was not significant, but there were separate
time and supplement effects (P , 0.0001) such that, over the fol-
low-up period of 28 d, the mean difference of 13C-DHA at each
time was not significantly lower while subjects were taking the
supplement than at baseline. However, the AUC of plasma 13C-
DHA while subjects were taking the supplement was 60% lower
than at baseline (P , 0.0001; Figure 3A). The rising slope of
plasma 13C-DHA was the same at baseline as while subjects were
taking the supplement (Figure 3A).
Plasma tracee (12C-DHA; nmol/L) was stable over the 28-
d follow-up period and was w70% higher while subjects were
taking the supplement than at baseline. The specific activity is
presented in Figure 3B and defined as 13C-DHA/12C-DHA. At
baseline, the peak specific activity was 1.12 6 0.08% compared
with 0.53 6 0.04% while subjects were taking the supplement,
with a significant time 3 supplement interaction (P , 0.0001)
that showed that the kinetics of specific activity over 28 d dif-
fered significantly in participants while they were taking the
FIGURE 2. Mean (6SEM) DHA in plasma total lipids over the 5-mo
supplementation period. One month after subjects started taking the supple-
ment, the concentration of DHA doubled in plasma total lipids and reached
a plateau (n = 34).
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supplement than at baseline. The specific activity was 2.5–7-
times higher at baseline than while subjects were taking the
supplement throughout the metabolic follow-up period 1–28
d postdose (Figure 3B).
There was a significant time 3 supplement interaction for
plasma 13C-EPA with 2.0–2.8-times higher plasma 13C-EPA
from 8 h to 7 d postdose while subjects were taking the sup-
plement than at baseline (Figure 3C). The specific activity of
plasma 13C-EPA was significantly different over time (P ,
0.0001), but there was no supplement effect and no interaction
(Figure 3D).
The cumulative b oxidation of 13C-DHA to 13C-CO2 over 28
d was 1.9-times higher while subjects were taking the supple-
ment than at baseline (Figure 4). The peak 13C-CO2 enrichment
occurred 4 h postdose and reached 0.48% of dose of 13C-DHA/h
while subjects were taking the supplement compared with
0.31% of dose per hour at baseline (data not shown). The en-
richment of 13C-CO2 returned almost to baseline 28 d postdose
at baseline and while subjects were taking the supplement (data
not shown). The cumulative b oxidation at 28 d was 35.1 6
6.7% of the tracer dose at baseline compared with 65.7 6 9.1%
while subjects were taking the supplement (Figure 4).
DHA half-life
The man plasma half-life of 13C-DHA was 4.5 6 0.4 d at
baseline compared with 3.0 6 0.2 d while subjects were taking
the supplement (P , 0.0001; Figure 5A). The mean whole-
body half-life of 13C-DHAwas 1406 27 d at baseline compared
with 54 6 12 d while subjects were taking the supplement (P =
0.0107; Figure 5B). Neither the plasma nor whole-body 13C-
DHA half-life differed between men and women, and there was
not a significant correlation with the age of participants.
Hierarchical linear model
The final estimation of the HLM model is shown in Figure 6.
At baseline, 13C-DHAwas positively related to PDR as 13C-CO2
with a slope of 0.0847, whereas while subjects were taking the
supplement, the slope was much steeper at 0.2076 (P , 0.001),
which showed that, for a similar concentration of 13C-DHA in
FIGURE 3. Mean (6SEM) concentrations of 13C-DHA (A), 13C/12C-DHA (B), 13C-EPA (C) 13C/12C-EPA (D) in plasma total lipids over 28 d at baseline
and while subjects were taking the supplement (n = 34). Statistics were performed by using the PROC MIXED procedure implemented in SAS 9.2 software
(SAS) and tested the effect of time as a repeated measure, supplementation as a fixed factor (baseline compared with supplement), and the interaction of time
3 supplement. When there was an interaction, comparisons at each time were performed by using a paired t test. For the AUC in A, a paired t test was
performed. In A, the 13C-DHA concentration varies significantly over time, and there was an independent supplement effect. In B and C, there was a time 3
supplement interaction. In D, 13C-EPA/12C-EPA varied significantly over time only (*P , 0.05). 12C-DHA; uniformly carbon-12–labeled DHA; 12C-EPA,
uniformly carbon-12–l labeled EPA; 13C-DHA, uniformly carbon-13–labeled DHA; 13C-EPA, uniformly carbon-13–l labeled EPA.
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blood, the b oxidation of 13C-DHA to 13C-CO2 was higher while
subjects were taking the supplement than at baseline. Plasma
13C-DHA explained 50% of the PDR variation in the model. The
intersubject variation (ui) associated with random effect (bkj)
was tested by using age, sex, education, and BMI as covariates
(see supplemental Text for a description of the mathematical
model under “Supplemental data” in the online issue). BMI was
the only covariate to be significantly involved in explaining the
intercept and contributed tow5% of the variation in the relation
between PDR and plasma 13C-DHA.
DISCUSSION
In this study, we report that supplementation with an EPA +
DHA supplement significantly modified the kinetics of 13C-DHA
in healthy older persons without cognitive decline such that its
plasma and whole-body half-lives were lower and its b oxida-
tion to 13C-CO2 was higher than at baseline. Hence, the pla-
teauing of plasma DHA at higher intakes of EPA + DHA
appears to be a function of increased b oxidation.
Despite the higher b oxidation of DHA while subjects were
taking the supplement, the cumulative b oxidation of 13C-DHA
remained low compared with what has typically been reported
for other long-chain fatty acids. For example, 24 h postdose, the
b oxidation of 13C-DHA was ,7% while subjects were taking
the supplement and at baseline (Figure 4), whereas the b oxi-
dation over the same period and under essentially the same
conditions was 29% for 13C-oleic acid, 21% for 13C–linoleic
acid, and 31% for 13C-a–linolenic acid (20). These results were
potentially because, in contrast to PUFAs with ,20 carbons,
PUFAs with .20 carbons require the previous peroxisomal b
oxidation to shorten the fatty acid chain before entry to the
mitochondrial b oxidation spiral (24, 25). However, the relative
contribution of peroxisomal compared with mitochondrial b
oxidation to the whole-body production of 13C-CO2 from
13C-
DHA in humans is unknown. The affinity of carnitine palmitoyl
transferase is also much lower for DHA than long chain fatty
acids with 1–3 double bonds (26). Thus, DHA is relatively ef-
ficiently conserved, probably because of its structural impor-
tance in cell membranes (27) and as a precursor to signaling
molecules (28).
Our 13C-CO2 breath results did not account for the
13C that
was converted to ½AQ913C-acetyl-CoA but then recovered in other
metabolites rather than entering the Krebs’ cycle and being
converted to 13C-CO2. However, during our gas chromatogra-
phy–combustion isotope ratio mass spectrometry analysis, there
was no measurable 13C enrichment in any other plasma fatty
acids except EPA, which suggested that, once 13C-DHA starts to
be b-oxidized, the process goes mostly to completion (ie,
quantitatively to 13C-CO2).
The whole-body half-life was calculated from the 13C-CO2
recovery in the breath to estimate the time needed to b oxidize
50% of the 13C-DHA dose without regard to compartments. In
this calculation, it was assumed that the quantity of 13C-CO2
going from peripheral compartments to plasma and then to
breath remained constant after the 28th d for ½AQ10subjects who did
FIGURE 4. Mean (6SEM) cumulative percentage of dose of 13C-DHA
b-oxidized and recovered in the breath as 13C-CO2 at baseline (gray squares)
and while subjects were taking the supplement (black triangles) (n = 34).
Statistics were performed using a PROC MIXED procedure implemented
SAS 9.2 software (SAS) and tested the effect of time as a repeated measure,
supplementation as a fixed factor (baseline compared with supplement), and
the interaction of time 3 supplement. When there was an interaction, com-
parisons at each time point were performed by using a paired t test. There
was a time 3 supplement interaction supporting that the difference in cu-
mulative 13C-CO2 expired while subjects were taking the supplement; base-
line was not the same at each time point (*P , 0.05). 13C-CO2, carbon
dioxide labeled with carbon-13; 13C-DHA, uniformly carbon-13–labeled
DHA.
FIGURE 5. Mean (6SEM) calculated half-life of 13C-DHA at baseline
and while subjects were taking the supplement in plasma total lipids (n = 32
at baseline and n = 34 while subjects were taking the supplement) (A) and
the whole body (n = 29 at baseline and n = 32 while subjects were taking the
supplement) (B). Paired t tests were performed for comparison of while
subjects were taking the supplement with at baseline. At baseline, blood
samples collected at 14, 21, and/or 28 d because 2 participants had an
enrichment of 13C over 12C below the enrichment at 0 h of day 0, and thus,
it was not possible to calculate the plasma half-life in these participants. In 5
participants at baseline and 2 participants while taking the supplement, the
cumulative b oxidation of 13C-DHA recovered as carbon dioxide labeled
with carbon-13 reached a plateau of ,50% 7 d postdose, and thus, the
calculation of the whole-body 13C-DHA half-life was not possible. While
subjects were taking the supplement, plasma and whole-body half-lives were
33–61% lower compared with at baseline. *P # 0.05. 13C-DHA, uniformly
carbon-13–labeled DHA.
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not reach 50% of cumulative 13C-CO2. Hence, the calculated
whole-body half-life represents the best estimate of the time
needed for one-half of the 13C-DHA dose to be exhaled in the
form of 13C-CO2 by participants, with the recognition that this is
probably an underestimate because some b-oxidized 13C-DHA
could theoretically get incorporated into other compounds syn-
thesized via 13C-acetyl-CoA.
The lower postprandial specific activity of plasma 13C-DHA
while subjects were taking the supplement can largely be ex-
plained by the 70% tracer dilution compared with at baseline
(Figure 3B). 13C-DHA kinetics may also have been affected
because the supplement was not pure DHA but rather a combi-
nation of EPA + DHA. The provision of pure DHA results in an
apparently linear increase in EPA in plasma phospholipids (16).
Therefore, if the supplement had been pure DHA, it is possible
that the 13C-EPA concentration in plasma would have been
higher than we observed, but this possibility is necessarily
speculative. Similarly, had the supplement provided a dose of
EPA + DHA closer to the international recommendation (rather
than 6 times above the recommendation as was the case in this
study), the effect on 13C-DHA kinetics would likely have been
attenuated.
Unlike the specific activity of plasma 13C-DHA, the specific
activity of plasma 13C-EPA was not significantly lower while
subjects were taking the supplement than at baseline (Figure 3D)
despite the EPA + DHA supplement having raised plasma EPA
5-fold. Changes in the mass of 13C-EPA during EPA + DHA
supplementation may originate via several routes, including the
retroconversion from DHA, carbon recycling that provides 13C-
acetyl-CoA for stearidonic acid elongation, and/or the sparing of
EPA from b oxidation. No change in the specific activity of
plasma EPA suggested that EPA sparing was significant while
subjects were taking the supplement. Because of the bigger pool
of circulating 13C-DHA, the apparent rate of retroconversion to
EPA or displacement of EPA from nonplasma pools appears to
have been unchanged by the supplement. In contrast, the slope
of 13C-DHA b oxidation increased with higher circulating DHA
while participants were taking the supplement than at baseline
(Figure 6). These data suggest that the partitioning of DHA
between b oxidation and retroconversion to EPA are probably
regulated separately.
In the current study, there was no difference in plasma 13C-
DHA, plasma DHA, or the 13C-DHA half-life in whole body or
plasma between men and women (data not shown). The absence
of sex-specific differences was probably because of the drop in
estrogen in women after menopause (29). Two other factors that
potentially change DHA homeostasis are age and APOE4 ge-
notype (7, 14). APOE4 carriers were excluded from this study
(15). Age-dependent differences in 13C-DHA metabolism have
been reported elsewhere over a 50-y difference in age (7). In the
current study, there was no correlation between age (52–90 y
old) and the 13C-DHA half-life, but this study was not designed
to assess a possible age effect. Participants in this study were of
an age when cognitive decline could be starting, but they were
all cognitively healthy as assessed by using the Mini-Mental
State Examination. This fact is important because we wanted to
eliminate lower cognitive performance as a confounder that
might have influenced the results (10).
In conclusion, in older persons taking 3.2 g EPA + DHA/d,
there is an increased b oxidation of 13C-DHA and shortened
plasma and whole-body 13C-DHA half-life. Therefore, when
circulating concentrations of EPA + DHA are increased, more
DHA appears to be available for b oxidation.
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